Notice of Results

RNS Number : 1445K

Life Science REIT PLC

03 May 2022

 

3 May 2022

LEI: 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Notice of Results for the period ended 31 December 2021

Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that it will report its financial results for the period ended 31 December 2021 on Monday 23 May 2022.

An online meeting for analysts will be held at 9.30am on the morning of the results announcement and will be hosted by Simon Farnsworth, Managing Director, and David Lewis, Director of Operations and Finance, at Ironstone Asset Management, the Company's Investment Adviser. For further details, please contact [e-mail].

The date of the results has been moved from 11 May 2022 to enable the Investment Adviser to prioritise current, late-stage discussions in connection with its acquisition pipeline.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Ironstone Asset Management - Investment Adviser
Simon Farnsworth	via Buchanan below
Panmure Gordon - Nominated Adviser and Joint Corporate Broker	[phone]
Atholl Tweedie / Sapna Shah / Philip Shields / Chloe Ponsonby
Jefferies International Limited - Joint Corporate Broker	[phone]
Tom Yeadon / Andrew Morris / Oliver Nott
Buchanan - Financial PR	[phone]
Mark Court / Henry Wilson / Verity Parker [e-mail]

Notes to editors

Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector. 

The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to occupiers operating in the life science sector in the UK. 

Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk

 

END

 

 

NORFLFEFERIVIIF